Maxim analyst Anthony Vendetti upgraded Nexalin Technology (NXL) to Buy from Hold with a $5 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin receives a Notice of Allowance from USPTO for patent on DIFS
- Nexalin Technology announces initiation of patient recruitment in UCSD study
- Nexalin Technology appoints Wesley Clark to Military, Government Advisory Board
- Nexalin Technology’s HALO Clarity headset approved for use in trials by UCSD
- Nexalin appointed industry co-chair of National TBI Registry Coalition